| Accession |
PRJCA026580 |
| Title |
Adjuvant Osimertinib in Non-small Cell Lung Cancer (NSCLC) with Uncommon Epidermal Growth Factor Receptor Mutations (EGFRm) |
| Relevance |
Lung cancer |
| Data types |
Exome
Targeted Locus (Loci)
Variation
|
| Organisms |
Homo sapiens
|
| Description |
This is an open-label, multi-centre, single-arm study assessing the efficacy and safety of osimertinib as adjuvant treatment in stage IB-IIIB (8th AJCC) NSCLC with uncommon EGFRm after receiving complete surgical resection with or without adjuvant chemotherapy |
| Sample scope |
Multiisolate |
| Release date |
2024-05-29 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Astrazeneca Investment (China) Co., Ltd.
|
|
2022LP00139
|
|
|
|
| Submitter |
Lunxu
Liu (acz855lunxuliu@163.com)
|
| Organization |
West China Hospital, Sichuan University |
| Submission date |
2024-05-29 |
